Sid Sankaran
Known title: President and CEOCIK: 0001509066
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SiriusPoint (SPNT) Valuation Questioned After Recent Price Rise. Recent market discussion has focused on whether SiriusPoint remains undervalued following a recent increase in its share price. The company currently trades with a low trailing P/E ratio of 5.7, which is significantly below the average analyst target of $28.75. This valuation gap has prompted investors to reassess the stock's position within its 52-week range of $17.39 to $26.50.
Transaction History
| OSCR | ▲ Buy | Grant | 8,475 | $0 | 6/4/2026 | View on chart |
| OSCR | ▲ Buy | Grant | 14,134 | $0 | 6/4/2025 | View on chart |
| OSCR | ▼ Sell | Gift | 295,687 | $0 | 2/7/2025 | View on chart |
| OSCR | ▼ Sell | Gift | 295,687 | $0 | 2/7/2025 | View on chart |
| OSCR | ▼ Sell | Open Market | 139,635 | $873K | 9/5/2023 | View on chart |
| OSCR | ▲ Buy | Option Exercise | 227,848 | — | 9/1/2023 | View on chart |
| OSCR | ▼ Sell | Open Market | 137,826 | $985K | 6/2/2023 | View on chart |
| OSCR | ▲ Buy | Option Exercise | 227,848 | — | 6/1/2023 | View on chart |
| OSCR | ▼ Sell | Open Market | 110,396 | $524K | 3/2/2023 | View on chart |
| OSCR | ▲ Buy | Option Exercise | 227,848 | — | 3/1/2023 | View on chart |
| SPNT | ▼ Sell | Tax Withholding | 21,130 | $138K | 4/14/2022 | View on chart |
| SPNT | ▲ Buy | Grant | 509,657 | $0 | 4/6/2022 | View on chart |
| SPNT | ▲ Buy | Grant | 37,826 | $0 | 4/6/2022 | View on chart |
| SPNT | ▼ Sell | Tax Withholding | 70,512 | $525K | 2/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Oscar Health Analyst Target Rises to $34.19
Analysts raised the consensus price target for Oscar Health by 12.09% to $34.19. This adjustment follows recent updates to the company's earnings roadmap and new product initiatives. The stock is currently trading near the upper end of its 52-week range, reflecting renewed interest in its growth prospects.
Oscar Health Analyst Target Rises to $34.19. Analysts raised the consensus price target for Oscar Health by 12.09% to $34.19. This adjustment follows recent updates to the company's earnings roadmap and new product initiatives. The stock is currently trading near the upper end of its 52-week range, reflecting renewed interest in its growth prospects.